These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 11480454)

  • 1. Relative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells.
    Morikawa S; Umetani M; Nakagawa S; Yamazaki H; Suganami H; Inoue K; Kitahara M; Hamakubo T; Kodama T; Saito Y
    J Atheroscler Thromb; 2000; 7(3):138-44. PubMed ID: 11480454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pravastatin inhibited the cholesterol synthesis in human hepatoma cell line Hep G2 less than simvastatin and lovastatin, which is reflected in the upregulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase and squalene synthase.
    Cohen LH; van Vliet A; Roodenburg L; Jansen LM; Griffioen M
    Biochem Pharmacol; 1993 Jun; 45(11):2203-8. PubMed ID: 8517861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of HMG-CoA reductase, apoprotein-B and LDL receptor gene expression by the hypocholesterolemic drugs simvastatin and ciprofibrate in Hep G2, human and rat hepatocytes.
    Qin W; Infante J; Wang SR; Infante R
    Biochim Biophys Acta; 1992 Jul; 1127(1):57-66. PubMed ID: 1627634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abnormal regulation of the LDL-R and HMG CoA reductase genes in subjects with familial hypercholesterolemia with the "French Canadian mutation".
    Yu L; Qiu S; Genest J
    Atherosclerosis; 1996 Jul; 124(1):103-17. PubMed ID: 8800498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential regulation of apolipoprotein B secretion from HepG2 cells by two HMG-CoA reductase inhibitors, atorvastatin and simvastatin.
    Wilcox LJ; Barrett PH; Huff MW
    J Lipid Res; 1999 Jun; 40(6):1078-89. PubMed ID: 10357840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Attenuation of plasma low density lipoprotein cholesterol by select 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in mice devoid of low density lipoprotein receptors.
    Bisgaier CL; Essenburg AD; Auerbach BJ; Pape ME; Sekerke CS; Gee A; Wölle S; Newton RS
    J Lipid Res; 1997 Dec; 38(12):2502-15. PubMed ID: 9458274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of a novel squalene epoxidase inhibitor, NB-598, on the regulation of cholesterol metabolism in Hep G2 cells.
    Hidaka Y; Hotta H; Nagata Y; Iwasawa Y; Horie M; Kamei T
    J Biol Chem; 1991 Jul; 266(20):13171-7. PubMed ID: 1649182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atorvastatin and simvastatin have distinct effects on hydroxy methylglutaryl-CoA reductase activity and mRNA abundance in the guinea pig.
    Conde K; Roy S; Freake HC; Newton RS; Fernandez ML
    Lipids; 1999 Dec; 34(12):1327-32. PubMed ID: 10652993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of different inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, pravastatin sodium and simvastatin, on sterol synthesis and immunological functions in human lymphocytes in vitro.
    Kurakata S; Kada M; Shimada Y; Komai T; Nomoto K
    Immunopharmacology; 1996 Aug; 34(1):51-61. PubMed ID: 8880225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atorvastatin action involves diminished recovery of hepatic HMG-CoA reductase activity.
    Ness GC; Chambers CM; Lopez D
    J Lipid Res; 1998 Jan; 39(1):75-84. PubMed ID: 9469588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of the low density lipoprotein receptor and hydroxymethylglutaryl coenzyme A reductase genes by protein kinase C and a putative negative regulatory protein.
    Auwerx JH; Chait A; Deeb SS
    Proc Natl Acad Sci U S A; 1989 Feb; 86(4):1133-7. PubMed ID: 2919164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HMG-CoA reductase activity in human liver microsomes: comparative inhibition by statins.
    Dansette PM; Jaoen M; Pons C
    Exp Toxicol Pathol; 2000 May; 52(2):145-8. PubMed ID: 10965989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The magnitude of decrease in hepatic very low density lipoprotein apolipoprotein B secretion is determined by the extent of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition in miniature pigs.
    Burnett JR; Wilcox LJ; Telford DE; Kleinstiver SJ; Barrett PH; Newton RS; Huff MW
    Endocrinology; 1999 Nov; 140(11):5293-302. PubMed ID: 10537160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of compactin, mevalonate and low-density lipoprotein on 3-hydroxy-3-methylglutaryl-coenzyme A reductase activity and low-density-lipoprotein-receptor activity in the human hepatoma cell line Hep G2.
    Cohen LH; Griffioen M; Havekes L; Schouten D; van Hinsbergh V; Kempen HJ
    Biochem J; 1984 Aug; 222(1):35-9. PubMed ID: 6089762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatic responses to inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase: a comparison of atorvastatin and simvastatin.
    Bergstrom JD; Bostedor RG; Rew DJ; Geissler WM; Wright SD; Chao YS
    Biochim Biophys Acta; 1998 Jan; 1389(3):213-21. PubMed ID: 9512650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of 3-hydroxy-3-methylglutaryl-CoA reductase mRNA contents in human hepatoma cell line Hep G2 by distinct classes of mevalonate-derived metabolites.
    Cohen LH; Griffioen M
    Biochem J; 1988 Oct; 255(1):61-7. PubMed ID: 2848511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In-vitro effect of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors on non-hepatic LDL receptor activity: evidence of lack of stimulatory effect of pravastatin.
    Pedreño J; Sánchez JL; Zambón D; Ros E
    Coron Artery Dis; 1994 Dec; 5(12):971-7. PubMed ID: 7728297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypocholesterolemic effects of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in the guinea pig: atorvastatin versus simvastatin.
    Conde K; Pineda G; Newton RS; Fernandez ML
    Biochem Pharmacol; 1999 Oct; 58(7):1209-19. PubMed ID: 10484079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H; Fager G
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies.
    Pasha MK; Muzeeb S; Basha SJ; Shashikumar D; Mullangi R; Srinivas NR
    Biomed Chromatogr; 2006 Mar; 20(3):282-93. PubMed ID: 16143964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.